drugset / Trial / NCT06178718
A Phase 1 Study to Evaluate PK Profile and Food Effects on PK Parameters of TNP-2092 Capsules
Phase 1
Completed
58 enrolled
TenNor Therapeutics Inc.
The First Hospital of Jilin University · collab
RandomizedSequentialDouble-blindTreatment
Summary
The aim of the study was to evaluate the tolerability and pharmacokinetic characteristics of TNP-2092 Capsules after single-dose administration in healthy subjects, and the food effect on pharmacokinetics.
Timeline
- Start
- 2016-06-06
- Primary completion
- 2016-08-02
- Completion
- 2016-08-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RIFAQUIZINONE | Small molecule | 100 mg | Oral |
| Subject | RIFAQUIZINONE | Small molecule | 200 mg | Oral |
| Subject | RIFAQUIZINONE | Small molecule | 400 mg | Oral |
| Subject | RIFAQUIZINONE | Small molecule | 800 mg | Oral |
| Subject | RIFAQUIZINONE | Small molecule | 1200 mg | Oral |
Indications
No indication recorded.